Skip to main content

Table 1 Characteristics of study participants who had been hospitalized with COVID-19

From: Changes in patients’ outlook, behaviors, and attitudes toward COVID-19 after hospitalization and their experiences of discrimination and harassment

 

All

1st wave

2nd wave

N

n (%)

M (SD)

N

n (%)

M (SD)

N

n (%)

M (SD)

Sex (male)

27

16 (59.3)

 

16

11 (68.8)

 

11

5 (45.5)

 

Age

27

 

50.0 (17.8)

16

 

48.4 (15.2)

11

 

52.5 (21.6)

Known residence

26

  

15

  

11

  

 Tamba City

 

0 (0.0)

  

0 (0.0)

  

0 (0.0)

 

 Tamba Sasayama City

 

2 (7.7)

  

0 (0.0)

  

2 (18.2)

 

 Others

 

24 (92.3)

  

15 (100.0)

  

9 (81.8)

 

Occupation (medical or nursing care-associated professions)

24

2 (8.3)

 

14

2 (14.3)

 

10

0 (0.0)

 

Living alone

25

6 (24.0)

 

15

2 (13.3)

 

10

2 (13.3)

 

Reasons for undergoing polymerase chain reaction test

26

  

15

  

11

  

Symptomatic patients without close contact with infected individuals

 

11 (42.3)

  

5 (33.3)

  

6 (54.6)

 

 Patients who visited a cluster site

 

2 (7.7)

  

1 (6.7)

  

1 (9.1)

 

 Patients who had a close contact with infected individuals

 

11 (42.3)

  

9 (60.0)

  

2 (18.2)

 

 Others

 

2 (7.7)

  

0 (0.0)

  

2 (18.2)

 

Symptoms present on admission

27

19 (70.4)

 

27

12 (75.0)

 

27

7 (63.6)

 

 Fever

27

12 (44.4)

 

27

8 (50.0)

 

27

4 (36.4)

 

 Cough

27

9 (33.3)

 

27

5 (31.3)

 

27

4 (36.4)

 

 Sputum

27

6 (22.2)

 

27

2 (12.5)

 

27

4 (36.4)

 

 Sore throat

27

4 (14.8)

 

27

2 (12.5)

 

27

2 (18.2)

 

 Nasal discharge

27

1 (3.7)

 

27

0 (0.0)

 

27

1 (9.1)

 

 Wheezing

27

1 (3.7)

 

27

1 (6.3)

 

27

0 (0.0)

 

 Dyspnea

27

4 (14.8)

 

27

4 (25.0)

 

27

0 (0.0)

 

 Chest pain

27

1 (3.7)

 

27

1 (6.3)

 

27

0 (0.0)

 

 Myalgia

27

1 (3.7)

 

27

1 (6.3)

 

27

0 (0.0)

 

 Arthralgia

27

2 (7.4)

 

27

1 (6.3)

 

27

1 (9.1)

 

 Headache

27

7 (25.9)

 

27

3 (18.8)

 

27

4 (36.4)

 

 Impaired consciousness

27

1 (3.7)

 

27

1 (6.3)

 

27

0 (0.0)

 

 Physical lassitude

27

10 (37.0)

 

27

8 (50.0)

 

27

2 (18.2)

 

 Abdominal pain

27

0 (0.0)

 

27

0 (0.0)

 

27

0 (0.0)

 

 Nausea

27

4 (14.8)

 

27

3 (18.8)

 

27

1 (9.1)

 

 Vomiting

27

0 (0.0)

 

27

0 (0.0)

 

27

0 (0.0)

 

 Diarrhea

27

5 (18.5)

 

27

3 (18.8)

 

27

2 (18.2)

 

 Taste disorder

27

7 (25.9)

 

27

4 (25.0)

 

27

3 (27.3)

 

 Smell disorder

27

7 (25.9)

 

27

4 (25.0)

 

27

3 (27.3)

 

Treatment administered

27

7 (25.9)

 

27

4 (25.0)

 

27

3 (27.3)

 

 Antipyretic analgesics

27

7 (25.9)

 

27

4 (25.0)

 

27

3 (27.3)

 

 Oral medicines for coronavirus

27

0 (0.0)

 

27

0 (0.0)

 

27

0 (0.0)

 

 Inhalants for coronavirus

27

0 (0.0)

 

27

0 (0.0)

 

27

0 (0.0)

 

 Oxygen therapy

27

1 (3.7)

 

27

1 (6.3)

 

27

0 (0.0)

 

 Mechanical ventilation

27

2 (7.4)

 

27

2 (12.5)

 

27

0 (0.0)

 

Length of hospital stay

27

 

10.4 (6.8)

16

 

11.8 (8.3)

11

 

8.3 (2.8)

Length of hotel stay for isolation

27

 

5.4 (7.6)

16

 

8.9 (8.2)

11

 

0.2 (0.6)

Period when the patients missed work or were unable to perform usual activities of daily living before hospitalization

24

 

5.8 (7.1)

14

 

6.1 (5.8)

10

 

5.4 (9.0)

Time that passed before being able to perform usual activities of daily living or resume work after returning home (from the hospital or the hotel for isolation)

25

 

9.4 (10.4)

15

 

10.9 (12.5)

10

 

7.2 (6.0)

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us